Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer | Zendy

Valerie W. Rusch | Zendy; Alan Nicholas | Zendy; G. Alexander Patterson | Zendy; Salama N. Waqar | Zendy; Eric M. Toloza | Zendy; Eric B. Haura | Zendy; Dan J. Raz | Zendy; Karen L. Reckamp | Zendy; Robert E. Merritt | Zendy; Dwight H. Owen | Zendy; David J. Finley | Zendy; Ciaran McNamee | Zendy; Justin D. Blasberg | Zendy; Edward B. Garon | Zendy; John D. Mitchell | Zendy; Robert C. Doebele | Zendy; Frank A. Baciewicz | Zendy; Misako Nagasaka | Zendy; Harvey I. Pass | Zendy; Katja Schulze | Zendy; Ann Johnson | Zendy; Paul A. Bunn | Zendy; Bruce E. Johnson | Zendy; Mark G. Kris | Zendy; David J. Kwiatkowski | Zendy; Ignacio I. Wistuba | Zendy; Jamie E. Chaft | Zendy; David P. Carbone | Zendy; Jay M. Lee | Zendy

Open Access

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Author(s) -

Valerie W. Rusch,

Alan Nicholas,

G. Alexander Patterson,

Salama N. Waqar,

Eric M. Toloza,

Eric B. Haura,

Dan J. Raz,

Karen L. Reckamp,

Robert E. Merritt,

Dwight H. Owen,

David J. Finley,

Ciaran McNamee,

Justin D. Blasberg,

Edward B. Garon,

John D. Mitchell,

Robert C. Doebele,

Frank A. Baciewicz,

Misako Nagasaka,

Harvey I. Pass,

Katja Schulze,

Ann Johnson,

Paul A. Bunn,

Bruce E. Johnson,

Mark G. Kris,

David J. Kwiatkowski,

Ignacio I. Wistuba,

Jamie E. Chaft,

David P. Carbone,

Jay M. Lee

Publication year - 2022

Publication title -

journal of thoracic and cardiovascular surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.458

H-Index - 192

eISSN - 1085-8687

pISSN - 0022-5223

DOI - 10.1016/j.jtcvs.2022.10.007

Subject(s) - atezolizumab , medicine , oncology , lung cancer , neoadjuvant therapy , phases of clinical research , clinical trial , lung , cancer , surgery , immunotherapy , breast cancer , pembrolizumab

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research